Jan 5 2011
IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, has shipped its 3,000th iQ®200Automated Urine Microscopy Analyzer. In a ceremony at the Company's Chatsworth headquarters, Thomas, E. Warekois, Corporate Vice President and President of the Iris Diagnostics Business Unit, announced that the analyzer, an iQ®200 Elite™, was shipped to Sarasota Memorial Hospital in Sarasota, Fla., and includes a medallion identifying it as the 3,000th shipment.
"We are proud of this significant achievement to have placed 3,000 iQ200 analyzers globally since its introduction and launch in 2003," stated Mr. Warekois. "With our flagship iQ200 system, Iris Diagnostics has emerged as the world leader in automated urine microscopy and body fluids analysis and has been recognized through our market share position plus numerous industry awards for excellence in product and customer service, increasing productivity and efficiency in the lab, and improving patient care management through better diagnostics."
"The success of the iQ200 and our core urinalysis business with its expanding worldwide base, has been the cornerstone for growth and overall stability at IRIS," stated Cesar Garcia, Chairman, President and CEO of IRIS International. "The strength of the iQ200 and our core competencies in flow imaging technology and particle recognition algorithms to automate the analysis of cell forms and structures, continues to be the driving force behind the development of our new product pipeline as we expand our expertise into large new markets, including hematology, infectious disease, cancer diagnostics and personalized medicine," Mr. Garcia added.